Senator Investment Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Senator Investment Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-150,000	Closed	-$15.5M	–	48
2022 Q4	$15.5M	Sell	150,000 -500,000	-77%	-$46.9M	1.4%	23
2022 Q3	$55.1M	Sell	650,000 -200,000	-24%	-$17.8M	5.01%	3
2022 Q2	$70.4M	Buy	+850,000	New	+$67.7M	5.04%	3
2018 Q3	–	Sell	-1,000,000	Closed	-$94.2M	–	40
2018 Q2	$94.2M	Buy	+1,000,000	New	+$87.6M	0.94%	33
2017 Q4	–	Sell	-700,000	Closed	-$65.1M	–	55
2017 Q3	$65.1M	Buy	+700,000	New	+$61.9M	0.87%	32
2017 Q2	–	Sell	-800,000	Closed	-$70.2M	–	58
2017 Q1	$70.2M	Hold	800,000	–	–	0.86%	36
2016 Q4	$66.3M	Sell	800,000 -50,000	-6%	-$4.3M	1.01%	26
2016 Q3	$78.6M	Buy	850,000 +200,000	+31%	+$18.8M	1.04%	30
2016 Q2	$50.6M	Buy	650,000 +150,000	+30%	+$12.8M	0.81%	35
2016 Q1	$41.2M	Buy	+500,000	New	+$40.7M	0.54%	41

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Senator Investment Group's BMRN Position: Q1 2023 in Review

Senator Investment Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 150,000 shares — an estimated $15.5M sold.

Senator Investment Group first reported a position in BMRN in Q1 2016 and held it in 10 quarters. The position peaked at $94.2M in Q2 2018. 553 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Senator Investment Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Senator Investment Group sold 150,000 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $15.5M.
Senator Investment Group first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 10 quarters.
Senator Investment Group's BioMarin Pharmaceuticals position peaked at $94.2M in Q2 2018.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Senator Investment Group's 13F filing for Q1 2023, filed 12 May 2023.